Skip to main content
Indian Journal of Ophthalmology logoLink to Indian Journal of Ophthalmology
. 2023 Aug 1;71(8):3091–3094. doi: 10.4103/IJO.IJO_44_23

Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice

Mar Prieto del Cura 1,*,✉, María J C Carballés 1, Marina Sastre-Ibáñez 1,*
PMCID: PMC10538817  PMID: 37530286

Abstract

Purpose:

Vascular endothelial growth factor inhibitors (anti-VEGF) have been shown to be effective in the treatment of diabetic macular edema. However, there is little information about the systemic effects of intraocular administration of anti-VEGF drugs in patients with coexistent diabetic nephropathy because it can produce adverse renal effects.

Methods:

This retrospective cohort study analyzed the effect of intravitreal anti-VEGF drugs (bevacizumab, ranibizumab, or aflibercept) on eFGR and microalbuminuria (MicA) in patients with diabetic macular edema and nonproliferative retinopathy without chronic kidney disease (CKD).

Results:

Sixty-six patients were included, 54.5% male and 45.5% female, with a mean age of 66.70 ± 11.6 years. The mean follow-up of patients with antiangiogenic treatment was 42.5 ± 28.07 months, and the mean number of injections was 10.91 ± 7.54. In 12.1% of the cases, there was a worsening of the glomerular filtration rate (eFGR) and a 19.7% worsening of the microalbuminuria (MicA). The number of injections was not related to the worsening of the eFGR (P = 0.74) or the MicA (P = 0.239). No relationship was found between the type of drug and the deterioration of the GFR (P = 0.689) or the MicA (P = 0.53).

Conclusions:

Based on the results, there is a small proportion of patients with increase in MicA and the decrease in eFGR after anti-VEGF therapy, and these was no associated with the number of injection or the drug type. Ophthalmologists should be aware of renal damage in order to do a close monitoring of renal function and proteinuria after intravitreal administration of anti-VEGF mainly in hypertensive patients.

Keywords: Chronic kidney disease (CKD), diabetic macular edema, glomerular filtration rate (eFGR), microalbuminuria (MicA), vascular endothelial growth factor inhibitors (anti-VEGF)


Vascular endothelial growth factor inhibitors (anti-VEGF) have been shown to be effective in the treatment of diabetic macular edema.[1,2] Anti-VEGF agents can suppress plasma-free VEGF levels and has recognized risk of systemic side effects.[1,2,3,4] Kidney damage, due to glomerular injury, after intraocular administration of anti-VEGF drugs has been described.[5,6,7] This may be particularly important in patients with coexistent diabetic nephropathy,[8] but there is no clear association according to published studies.[9,10]

As diabetic macular edema is a frequent complication of diabetic retinopathy, the aim of our study was to assess whether the treatment with different anti-VEGF agents is associated with renal function deterioration.

Methods

This single-center retrospective cohort study analyzed the effect of intravitreal anti-VEGF drugs (bevacizumab, ranibizumab, or aflibercept) on estimated glomerular filtration rate (eGFR) and microalbuminuria (MicA) in diabetic patients with diabetic macular edema and nonproliferative diabetic retinopathy.

The protocol was approved by the ethics committee of Infanta Leonor Hospital, Madrid, Spain.

A total of 115 medical records of diabetic patients who received intravitreal VEGF inhibitors were reviewed; aflibercept (Eylea; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA), bevacizumab (Avastin; Genentech Inc., South San Francisco, CA, USA), and/or ranibizumab (Lucentis; Genentech Inc.), at the Ophthalmology Department of Infanta Leonor Hospital between December 1, 2019, and January 31, 2021.

Included patients had both baseline (1 month before injection) and follow-up (1 month after the last recorded injection) measurements of renal function parameters (GFR and MicA). Exclusion criteria were lack of available GFR or MicA data or renal failure requiring hemodialysis and/or intravitreal treatment with corticosteroids.

After written informed consent, the patient was injected with either with either 2.0 mg of aflibercept, 1.25 mg of bevacizumab or 0.5 mg of ranibizumab, into the vitreous cavity through the pars plana, 3.0–4.0 mm posterior to the limbus, using a 30-G needle under sterile conditions.

Measurements and end point

We registered sex, age, hypertension, ischemic heart disease, peripheral vascular disease, diabetic foot, diabetic polyneuropathy, drugs (aspirin, statins, renin–angiotensin system inhibitors, oral antidiabetics, and insulin), and years with diabetes. Also, months from the first intravitreal injection until the last doses (months), number of injections, and glycated hemoglobin (HbA1c) before and after the last intravitreal registered injection and type of response to treatment (partial, good, and no response). Hypertension and other systemic disorders were controlled by nephrologists during the antiVEGF treatment.

Renal function was assessed by eGFR and MicA. We used the kdigo classification to classify renal function (G1, G2, G3a, G3b, G4, and G5).[11] We registered if there was renal eGFR and/or MicA worsening (yes/no).

The primary end point was renal function worsening (yes/no), attending to eGFR and MicA, after VEGF inhibitor treatment. The secondary end point was to evaluate renal function worsening attending to renal function stage.

Statistical analysis

Statistical analyses were performed with the SPSS program (21.0; IBM Corp., Armonk, NY). Quantitative data are expressed using mean and standard deviation (and range). For data not following Gaussian distribution median, interquartile range and maximum and minimum values are also given. Categorical variables will be expressed by absolute and percentage frequencies. To test the normality of the distributions in samples of less than 30, the Shapiro–Wilk test will be used, using in some cases the Kolmogorov–Smirnov test.

Qualitative variables will be compared using the c2 test (Fisher’s test if n <5 in any of the cells).

To test statistically significant differences in continuous variables, the Student’s t test for independent variables or the Mann–Whitney U test will be used. In the case of pre–post analyses of evolution, McNemar’s test will be used.

A P value < 0.05 will be considered significant.

Results

Sixty-six patients that met the inclusion criteria for enrollment were included, 54.5% male and 45.5% female, with a mean age of (± standard deviation) 66.70 ± 11.6 years (range 39–90). Demographics and basal measurements of the study patients are listed in Table 1.

Table 1.

Demographics and basal measurements

Characteristics Number of patients (%)
Sex
 Male (%) 36 (54,5%)
 Female (%) 30 (45,5%)
Age (years) 66.70±11.6
Hypertension
 YES n (%) 53 (80,3%)
 NO n (%) 13 (19,7%)
Renin–angiotensin inhibition treatment
 YES n (%) 48 (72,7%)
 NO n (%) 18 (27,3%)
Anti-aggregation
 YES n (%) 30 (45,5%)
 NO n (%) 36 (54,5%)
Statin treatment
 YES n (%) 48 (72,7%)
 NO n (%) 18 (27,3%)
Diabetic polyneuropathy
 YES n (%) 7 (10, 6%)
 NO n (%) 59 (89,4%)
Diabetic foot
 YES n (%) 9 (13,6%)
 NO n (%) 57 (86,4%)
Cerebrovascular disease
 YES n (%) 9 (13,6%)
 NO n (%) 57 (86,4%)
Diabetes diagnosis (years) 15,05±7,79
Pre-HbA1c (%) 8,3±2,09
Post-HbA1c (%) 7,49% ± 1,6.
Insulin treatment
 YES n (%) 41 (62,1%)
 NO n (%) 25 (37,9%)
Oral antidiabetic therapy
 YES n (%) 58 (87,9%)
 NO n (%) 8 (12,1%)
Glomerular filtration rate category
 G1 31 (47%)
 G2 16 (24,2%)
 G3A 12 (18,2%)
 G3B 5 (7,6%)
 G4 2 (3%)

*eGFR: Estimated glomerular filtration rate, †micA: Microalbuminuria

Average follow-up time was 42,45 ± 28,07 months (range 2,75–118), and patients received an average of 10.91 ± 7.54 injections (range 1–38). 24 patients (42,4%) had only one eye treated and 38 patients (57,57%) both eyes.

57.6% received bevacizumab, 9.1% aflibercept, and 33.3% a combination (bevacizumab and ranibizumab or aflibercept).

Anti-VEGF treatment was not related to renal function deterioration, 12,12% patients had eGFR worsening, and 19.7% of increased microalbuminuria (MicA) after treatment. When combining eGFR and/or MicA worsening we found 25,8% had renal function deterioration [Table 2]. Five of the eight patients (62,5%) with eFGR deterioration had > G3A of baseline renal function [Table 2].

Table 2.

Post anti-VEGF treatment data

Number of patients (%)
eGFR Worsening
 YES 8 (12,12%)
 NO 58 (87,88%)
micA Worsening
 YES 13 (19,7%)
 NO 53 (80,30%)
micA and/or eGFR worsening
 YES 17 (25,8%)
 NO 49(74,2%)
micA and/or eGFR worsening
 One eye treatment 4 (14,28%)
 both eye treatment 13 (34,21%)
Renal function and eFGR worsening No Yes
 G1 31 0
 G2 14 2
 G3A 9 3
 G3B 3 2
 G4 1 1

*eGFR: Estimated glomerular filtration rate. †micA: Microalbuminuria

The number of injections was not related to eGFR (P = 0.74), MicA (P = 0.239), or eGFR and/or MicA (P = 0,46) worsening. Patients with MicA and/or eGFR worsening received 9.94 ± 5.5 and those who did not 11.24 ± 8.1 injections. Moreover, those with increased microalbuminuria received an average of 9.92 ± 1.4 injections and patients without 11.15 ± 1.10. Patients with MicA and/or eGFR worsening received 9.94 ± 5.5, and those who did not 11.24 ± 8.1 injections.

Also, we analyzed if those patients with both eyes treated compared to one eye had more renal function worsening (MicA and/or eGFR) and found no differences between the groups (P = 0.09) [Table 2].

No relationship was found between the type of drug and eGFR (P = 0.689) or MicA (P = 0.53) deterioration.

Hypertensive patients (53), despite optimal control by nephrologists, presented renal function worsening (MicA and/or eGFR) compared to non-hypertensive patients (13) in patients receiving anti-VEGF treatment (P = 0.015).

Discussion

Systemic use of anti-VEGF agents for oncologic purposes has been observed to cause worsening of hypertension, proteinuria, and renal function, triggering various glomerular diseases.[12]

Although intravitreal anti-VEGF injection is generally supposed to be safe because there is little systemic absorption, there is growing evidence that they may contribute to proteinuria, impaired renal function, and hypertension.[13,14]

Pharmacokinetic studies have shown that although the dose used for intravitreal treatment is minimal, and detectable blood levels of 0.1-0.2 nmol/L of anti-VEGF inhibitors have been observed up to 30 days after intravitreal injection.

In normal conditions, there is a blockade by the ocular barrier that locally sequesters the drug and causes a delay in its systemic absorption. This barrier is damaged in patients with macular degeneration, macular edema caused by diabetic retinopathy, or by vascular occlusion and may cause more systemic abortion.[1]

The kidney has a high expression of VEGF and VEGF receptors. It is mainly expressed by podocytes, and it regulated the function of glomerular capillary cells and tubular endothelial cells.[15] VEGF has an essential role in the development and maintenance of the glomerular endothelium: it promotes the proliferation, differentiation, and survival of fenestrated endothelial cells in the differentiation and survival of mesangial cells, mediates vasodilation, induces microvascular hyperpermeability, and participates in the remodeling of the interstitial matrix.[16]

It has been described that continuous injection of anti-VEGF results in intravascular depletion of VEGF that affects trophic signaling to podocytes and endothelial cells and causes inflammation through the renal angiotensin aldosterone system (RAAS).[17]

We did not find renal filtration o microalbuminuria deterioration in our series after intravitreal anti-VEGF therapy in diabetic patients, suggesting that this therapy is safe in terms of renal function even in diabetic patients. These results support other authors that demonstrate no renal effects.[9,10,18]

Chung et al.[19] found that 80% of patients with diabetes showed no harmful effects in terms of albuminuria after anti-VEGF therapy; however, patients with baseline renal dysfunction showed relatively higher risk of worsening albuminuria. Hanna et al.[8] also described three cases of aggravated proteinuria after multiple intravitreal anti-VEGF injections that had preexisting renal dysfunction. These results suggest a possible increased relative risk of renal function worsening in patients with renal dysfunction after treatment.

Although we cannot draw conclusions because of the small number of patients with decreased filtration rate at baseline, 62,5% of patients with GFR deterioration after anti-VEGF therapy had an advanced renal impairment stage, G3a (mild to moderately decreased GFR), or worse.

According to our results, patients with hypertension at baseline are more likely to worsen renal function compared to non-hypertensive patients receiving antiVEGF treatment. These results may support the idea that patients with renal dysfunction may need to be followed closely after this therapy specially in hypertensive patients. However, we cannot discard renal deterioration due to diabetic nephropathy, concomitant hypertension, and/or chronic kidney disease itself in these patients.[20,21,22]

Not all VEGF-blocking agents present the same renal risk according to different studies, being ranibizumab the safest drug.[1,23,24] Switching patients from bevacizumab and aflibercept to ranibizumab can decrease absorption and the risk of systemic side effects after intravitreal injections.[23]

Although we did not find differences within the different intravitreal therapies, most patients in our series received bevacizumab therapy only or in combination (57.6% bevacizumab and 33% combination) and are therefore difficult to draw conclusions.

While there is no concluding evidence that intravitreal anti-VEGF treatment deteriorates renal function, in patients with impaired kidney function or when proteinuria worsens, it is reasonable to consider decreasing the dose or switching to another agent with less systemic absorption and less severe systemic VEGF inhibition such as ranibizumab.[1,24]

Due to the widespread use of this type of drugs in a population as important as the diabetic population, stricter follow-up protocols should be established between ophthalmologists and nephrologists (blood pressure measurement, determination of proteinuria, and serum creatinine) before and after the administration of antiangiogenic drugs to establish an early diagnosis of possible renal complications.[25]

Limitations of the current study include the retrospective nature and the small number of included patients. We do not include patients with ranibizumab as only treatment, and patients with aflibercept only are scarce to be able to compare renal effects between drugs genuinely. Also, eGFR measurements are not as accurate as measured GFR, especially in early stages of kidney disease, but it is normally used in studies as it is widely available. Larger prospective studies are needed to be able to conclude that anti-VEGF agents are safe for all patients with or without renal disorder.

Conclusion

In conclusion, according to our results, anti-VEGF treatment does not produce kidney damage in most patients and suggest that those patients with pre-existing renal dysfunction should be closely monitored before and after intravitreal administration of anti-VEGF. Follow-up protocols could be established in diabetic patients between ophthalmologists and nephrologists to be able to detect early possible damage mainly in hypertensive patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  • 1.Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636–41. doi: 10.1136/bjophthalmol-2014-305252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema:A systematic review and meta-analysis. JAMA Ophthalmol. 2016;134:21–9. doi: 10.1001/jamaophthalmol.2015.4070. [DOI] [PubMed] [Google Scholar]
  • 3.Carneiro AM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25–30. doi: 10.1111/j.1755-3768.2011.02240.x. [DOI] [PubMed] [Google Scholar]
  • 4.Davidović SP, Nikolić SV, Curić NJ, Latinović SL, Drašković DO, Cabarkapa VS, et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol. 2012;22:792–8. doi: 10.5301/ejo.5000118. [DOI] [PubMed] [Google Scholar]
  • 5.Arevalo JF, Lasave AF, Wu L, Maia M, Diaz-Llopis M, Alezzandrini AA, et al. Intravitreal bevacizumab for proliferative diabetic retinopathy:Results from the Pan-American Collaborative Retina Study group (PACORES) at 24 months of follow-up. Retina. 2017;37:334–43. doi: 10.1097/IAE.0000000000001181. [DOI] [PubMed] [Google Scholar]
  • 6.Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, et al. Change in diabetic retinopathy through 2 years:Secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol. 2017;135:558–68. doi: 10.1001/jamaophthalmol.2017.0821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Touzani F, Geers C, Pozdzik A. Intravitreal injection of anti- VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;2019:2919080. doi: 10.1155/2019/2919080. doi:10.1155/2019/2919080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2019;12:92–100. doi: 10.1093/ckj/sfy060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kameda Y, Babazono T, Uchigata Y, Kitano S. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig. 2018;9:937–9. doi: 10.1111/jdi.12771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.O'Neill RA, Gallagher P, Douglas T, Little JA, Maxwell AP, Silvestri G, et al. Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20:478. doi: 10.1186/s12882-019-1650-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kidney Disease:Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1–87. doi: 10.1016/j.kint.2020.11.003. [DOI] [PubMed] [Google Scholar]
  • 12.Hanna RM, Lopez E, Wilson J, Barathan S, Cohen AH. Minimal change disease onset observed after bevacizumab administration. Clin Kidney J. 2016;9:239–44. doi: 10.1093/ckj/sfv139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond) 2009;23:1714–8. doi: 10.1038/eye.2008.360. [DOI] [PubMed] [Google Scholar]
  • 14.Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847–58. doi: 10.1097/IAE.0000000000001493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707–16. doi: 10.1172/JCI17423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Pellé G, Shweke N, Duong Van Huyen JP, Tricot L, Hessaïne S, Frémeaux-Bacchi V, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57:756–9. doi: 10.1053/j.ajkd.2010.11.030. [DOI] [PubMed] [Google Scholar]
  • 17.Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, et al. Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema. Ophthalmology. 2018;125:1054–63. doi: 10.1016/j.ophtha.2018.01.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Camp DA, Price DA, Neiweem AE, Jusufbegovic D. Effects of intravitreal bevacizumab therapy on glomerular filtration rates in patients treated for proliferative diabetic retinopathy. Retina. 2022;42:1926–30. doi: 10.1097/IAE.0000000000003562. [DOI] [PubMed] [Google Scholar]
  • 19.Chung Y-R, Kim YH, Byeon H-E, Jo DH, Kim JH, Lee K. Effect of a single intravitreal bevacizumab injection on proteinuria in patients with diabetes. Trans Vis Sci Tech. 2020;9:4. doi: 10.1167/tvst.9.4.4. doi:10.1167/tvst. 9.4.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Manaviat MR, Afkhami M, Shoja MR. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol. 2004;4:9. doi: 10.1186/1471-2415-4-9. doi:10.1186/1471-2415-4-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Moharram OA, Kangave D. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol. 2001;24:1–11. doi: 10.1023/a:1014409829614. doi:10.1023/a:1014409829614. [DOI] [PubMed] [Google Scholar]
  • 22.Lee WJ, Sobrin L, Lee MJ, Kang MH, Seong M, Cho H. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3) Invest Ophthalmol Vis Sci. 2014;55:6547–65. doi: 10.1167/iovs.14-15001. [DOI] [PubMed] [Google Scholar]
  • 23.Tschulakow A, Christner S, Julien S, Ludinsky M, van der Giet M, Schraermeyer U. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS One. 2014;9:e113701. doi: 10.1371/journal.pone.0113701. doi:10.1371/journal.pone.0113701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hanna RM, Abdelnour L, Hasnain H, Selamet U, Kurtz I. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. SAGE Open Med Case Rep. 2020;8 doi: 10.1177/2050313X20907033. 2050313X20907033. doi:10.1177/2050313X20907033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Georgalas I, Papaconstantinou D, Papadopoulos K, Pagoulatos D, Karagiannis D, Koutsandrea C. Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease -- A possible side effect? Curr Drug Saf. 2014;9:156–8. doi: 10.2174/1574886309666140211113635. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Ophthalmology are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES